Rationale for trastuzumab (herceptin) in adjuvant breast cancer trialsSLAMON, Dennis; PEGRAM, Mark.Seminars in oncology. 2001, Vol 28, Num 1, pp 13-19, issn 0093-7754, SUP3Article

New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (herceptin)NABHOLTZ, Jean-Marc; SLAMON, Dennis.Seminars in oncology. 2001, Vol 28, Num 1, pp 1-12, issn 0093-7754, SUP3Article

New Strategies in Adjuvant Breast Cancer Clinical TrialsNABHOLTZ, Jean-Marc; SLAMON, Dennis.Seminars in oncology. 2001, Vol 28, Num 1, issn 0093-7754, 45 p., SUP3Serial Issue

Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteinsFEJZO, Marlena Schoenberg; SLAMON, Dennis J.The American journal of pathology. 2001, Vol 159, Num 5, pp 1645-1650, issn 0002-9440Article

The platinum agents: a role in breast cancer treatment?CROWN, John P.Seminars in oncology. 2001, Vol 28, Num 1, pp 28-37, issn 0093-7754, SUP3Article

Docetaxel (taxotere) plus trastuzumab (herceptin) in breast cancerBURRIS, Howard A.Seminars in oncology. 2001, Vol 28, Num 1, pp 38-44, issn 0093-7754, SUP3Article

Cardiac toxicity of trastuzumab (herceptin): implications for the design of adjuvant trialsSPARANO, Joseph A.Seminars in oncology. 2001, Vol 28, Num 1, pp 20-27, issn 0093-7754, SUP3Article

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapyPEGRAM, Mark; SLAMON, Dennis.Seminars in oncology. 2000, Vol 27, Num 5, pp 13-19, issn 0093-7754, SUP9Conference Paper

Effects on Quality of Life of combined trastuzumab and chemotherapy in women with metastatic breast cancerOSOBA, David; SLAMON, Dennis J; BURCHMORE, Michael et al.Journal of clinical oncology. 2002, Vol 20, Num 14, pp 3106-3113, issn 0732-183XArticle

FOXO1A Is a Target for HER2-Overexpressing Breast TumorsYANYUAN WU; XIYING SHANG; SARKISSYAN, Marianna et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 13, pp 5475-5485, issn 0008-5472, 11 p.Article

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerROBERT, Nicholas; LEYLAND-JONES, Brian; ALBAIN, Kathy et al.Journal of clinical oncology. 2006, Vol 24, Num 18, pp 2786-2792, issn 0732-183X, 7 p.Article

A human ovarian carcinoma murine xenograft model useful for preclinical trialsELKAS, John C; BALDWIN, Rae Lynn; PEGRAM, Mark et al.Gynecologic oncology (Print). 2002, Vol 87, Num 2, pp 200-206, issn 0090-8258, 7 p.Article

A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3OH, Juliana J; WEST, Alison R; FISHBEIN, Michael C et al.Cancer research (Baltimore). 2002, Vol 62, Num 11, pp 3207-3213, issn 0008-5472Article

Treatment of meningeal breast cancer xenografts in the rat using an anti-P185/HER2 antibodyBERGMAN, Ira; BARMADA, Mamdouha A; GRIFFIN, Judith A et al.Clinical cancer research. 2001, Vol 7, Num 7, pp 2050-2056, issn 1078-0432Article

The molecular and cellular biology of HER2/neu gene amplification/ overexpression and the clinical development of herceptin (Trastuzumab) therapy for breast cancerPEGRAM, Mark D; KONECNY, Gottfried; SLAMON, Dennis J et al.Cancer treatment and research. 2000, Vol 103, pp 57-75, issn 0927-3042Article

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing : Biologic and Methodologic ConsiderationsSAUTER, Guido; LEE, James; BARTLETT, John M. S et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1323-1333, issn 0732-183X, 11 p.Article

The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancersOH, Juliana J; KOEGEL, Ashley K; PHAN, Diana T et al.Lung cancer. 2007, Vol 58, Num 1, pp 7-14, issn 0169-5002, 8 p.Article

Adjuvant Trastuzumab in HER2-Positive Breast CancerSLAMON, Dennis; EIERMANN, Wolfgang; PINTER, Tamas et al.The New England journal of medicine. 2011, Vol 365, Num 14, pp 1273-1283, issn 0028-4793, 11 p.Article

Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell CarcinomaKUO, Kuan-Ting; MAO, Tsui-Lien; SHIH, Ie-Ming et al.The American journal of pathology. 2009, Vol 174, Num 5, pp 1597-1601, issn 0002-9440, 5 p.Article

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancerKONECNY, Gottfried; FRITZ, Manuel; UNTCH, Michael et al.Breast cancer research and treatment. 2001, Vol 69, Num 1, pp 53-63, issn 0167-6806Article

Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaJONES, Siân; WANG, Tian-Li; KINZLER, Kenneth W et al.Science (Washington, D.C.). 2010, Vol 330, Num 6001, pp 228-231, issn 0036-8075, 4 p.Article

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off periodBRITTEN, Carolyn D; KABBINAVAR, Fairooz; HECHT, J. Randolph et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 3, pp 515-524, issn 0344-5704, 10 p.Article

RIN1 Is a Breast Tumor Suppressor GeneMILSTEIN, Marc; MOOSER, Chelsea K; HAILIANG HU et al.Cancer research (Baltimore). 2007, Vol 67, Num 24, pp 11510-11516, issn 0008-5472, 7 p.Article

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancerJOHNSTON, Stephen R. D; GÓMEZ, Henry; STEMMER, Salomon M et al.Breast cancer research and treatment. 2013, Vol 137, Num 3, pp 755-766, issn 0167-6806, 12 p.Article

Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancerKONECNY, Gottfried; UNTCH, Michael; PIHAN, Astrid et al.Clinical cancer research. 2001, Vol 7, Num 6, pp 1743-1749, issn 1078-0432Article